statistical comparison of a number of new tuberculosis vaccines.
statistical comparison of a number of new tuberculosis vaccines.
Ali Sookhtehsaraee,1Rezvan Dalvand,2Kazhal Shakarami,3Zahra Jadali,4Fatemeh Gandomkar,5Melika Zare,6,*
1. Student Research Commitee, Semnan University of Medical Sciences, Semnan, Iran 2. Student Research Commitee, Lorestan University of Medical Sciences, khorramabad, Iran 3. Student Research Commitee, Lorestan University of Medical Sciences, khorramabad, Iran 4. Student Research Commitee, Larestan University of Medical Sciences, larestan, Iran 5. Student Research Commitee, Jiroft University of Medical Sciences, Jiroft, Iran 6. Faculty of Paramedicine, Department of medicine, Shahrekord University of Medical Sciences ,Shahrekord, Iran
Introduction: Tuberculosis (TB) is one of the most dangerous diseases caused by Mycobacterium tuberculosis and is considered a major global and public health problem also TB is an airborne infection caused by Mycobacterium tuberculosis, which affects about 30% of the world's population also TB is the most common cause of death from an infectious pathogen .The high mortality rate increases the need to develop an effective vaccine but due to limit global resources, few vaccines can be upgraded to large-scale efficacy trials and our goal in this study was a detailed statistical comparison of a number of new TB vaccines.
Methods: In the forthcoming systematic review, the required data were collected using keywords and citing valid databases such as Scopus, PubMed, Google Scholar and ProQuest. The statistical population includes all studies conducted until 2022 in the field of statistical comparison of a number of new TB vaccines. After reviewing the relevant findings and evaluating the quality of the data, 17 similar articles were reviewed and analyzed, and the latest information on tuberculosis vaccines was studied from them.
Results: Tuberculosis is a major global problem and the only licensed vaccine is Bacillus Chalmette- Guerin (BCG), however, tuberculosis is still one of the main causes of morbidity and mortality in the world while the BCG vaccine is somewhat effective against severe tuberculosis in children and many new TB vaccines are designed to boost BCG, but the development of improved TB vaccines needs to overcome several challenges and one of the most important challenges is the lack of sufficient assurance in human clinical trials.
Conclusion: In general, the response of the human immune system in the field of vaccination requires the attention of more research to determine how successful the new tuberculosis vaccines will be in inducing humoral and cellular immunity.